精神分裂症复发现状与长效针剂在预防复发中作(总院讲座)用.pptVIP

目录 精神分裂症的复发 从循证医学和疾病的本质来认识精神分裂症的 复发问题 长效针剂在预防复发中的作用 以预防复发为目标的精神分裂症治疗理念 目录 精神分裂症的复发 从循证医学和疾病的本质来认识精神分裂症的 复发问题 长效针剂在预防复发中的作用 以预防复发为目标的精神分裂症治疗理念 新型长效针剂承载的新的治疗理念正在形成 各级治疗指南均强调急性期就应考虑长期维持的药物治 疗方案 各级治疗指南均指出药物长期维持治疗是预防复发的最关 键因素 新型长效针剂有天然优势（更好的疗效，可靠递药系统， 更好的安全性，更好的依从性，更稳定的血药浓度），适 合于精神分裂症的长期治疗 最新的棕榈酸帕利哌酮长效针剂独具精神分裂症急性期快 速起效及维持期稳定疗效，支持预防复发从急性期治疗开 始的治疗理念 总 结 精神分裂症本质上是高复发疾病，危害严重，我们必须正视这个挑战 新型长效针剂在预防复发上有着明确的优势 独具急性期快速起效症状控制和长期持续改善症状的新型长效针剂，将领导新的预防复发治疗理念的形成 谢 谢！ 1，去掉了针管图片，这不是善思达中国产品的图片，而且不适合出现在这里，因为长效针剂只是题目中的一部分 * Relapse prevention in schizophrenia Comprehensive Medical Education Slide Kit * 1.1 High rates of relapse among patients with schizophrenia The risk of relapse among patients with schizophrenia is known to be high in the early stages of the illness, as the results of this study of first-episode patients indicate.1 Relapse following response to treatment was evaluated in 104 patients with schizophrenia or schizoaffective disorder receiving open-label treatment (as required according to illness severity) for up to 5 years. Survival analysis was used to estimate the cumulative rate of relapse and to evaluate potential predictors of relapse. Despite initially responding to treatment, almost all the first-episode patients subsequently relapsed. The number remaining relapse-free was 80 after a year; 39 after 2 years; 22 after 3 years; and 9 after 4 years, and by the end of the study (year 5) only 4 patients had not relapsed. 2 years after the initial response, the cumulative relapse rate (for a first relapse) was 53.7% (95% CI=43.4–64.0), while after 5 years the cumulative first relapse rate was 81.9% (95% CI=70.6–93.2) Among patients who had a relapse and then responded to treatment (n=63), the cumulative rate for a second relapse was 78.0% (95% CI=46.5–100) after 5 years Among those who had a second relapse and then responded to treatment (n=20), the cumulative third relapse rate was 86.2% (95% CI=61.5–100) after 4 years. CI =